Increased prostate-specific membrane antigen (PSMA) expression on almost all types of PCa – and at the same time its limited physiological expression on majority of other tissues – makes it a very attractive molecular target for both therapeutic and imaging purposes (Al Saffar et al. 2024) In recent years, PSMA-targeted ligands have received a lot of attention, and researchers are still coming up with new ways to improve the pharmacokinetic and biodistribution properties over those currently used PSMA inhibitors (Ruigrok et al. 2021). The gene discussed is FOLH1; the disease is posterior cortical atrophy.